Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
Notified -
Globe Newswire7-07-2025, 18:00
AMD Brings World-Class Performance of 4th Gen AMD EPYC™ 14-03-2023, 15:06